Terms ending in 2040
Every in-force patent on Precision Biosciences, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,008,548 | Genetically-Modified Immune Cells Comprising a Microrna-Adapted Shrna (SHRNAMIR) In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,186,822 | Genetically-Modified Immune Cells Comprising a Microrna-Adapted Shrna (SHRNAMIR) In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,384,335 | Genetically-Modified Immune Cells Comprising a Microrna-Adapted Shrna (SHRNAMIR) In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,453,861 | Genetically-Modified Immune Cells Comprising a Microrna-Adapted Shrna (SHRNAMIR) In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,851,680 | Genetically-Modified Immune Cells Comprising a Microrna-Adapted Shrna (SHRNAMIR) In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,786,554 | Optimized Engineered Nucleases Having Specificity for the Human T Cell Receptor Alpha Constant Region Gene In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,680,254 | Engineered Meganucleases Specific for Recognition Sequences in the PCSK9 Gene In force · High confidence | Precision Biosciences, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.